Skip to Main Content

Paper Details

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.
Cardiol Ther
9
2022
Author NameAffiliation
Tara I ChangStanford University School of Medicine
Kenneth W MahaffeyStanford Center for Clinical Research, Stanford University School of Medicine
  • 1 - 2

Datasets

Release 1.2